Normal antipyrine metabolism in patients with cholesterol cholelithiasis

1975 ◽  
Vol 20 (1) ◽  
pp. 9-12 ◽  
Author(s):  
Gershon W. Hepner ◽  
Elliot S. Vesell
1978 ◽  
Vol 23 (10) ◽  
pp. 877-882 ◽  
Author(s):  
Glenn L. Goodhart ◽  
Matthew E. Levison ◽  
Bruce W. Trotman ◽  
Roger D. Soloway

1976 ◽  
Vol 20 (3) ◽  
pp. 369-376 ◽  
Author(s):  
Henry S. Fraser ◽  
Christopher J. Bulpitt ◽  
Clare Kahn ◽  
Geoffrey Mould ◽  
John C. Mucklow ◽  
...  

1984 ◽  
Vol 13 (3) ◽  
pp. 181-185 ◽  
Author(s):  
M. W. E. Teunissen ◽  
P. H. B. Willemse ◽  
D. T. Sleijfer ◽  
W. J. Sluiter ◽  
D. D. Breimer

Lipids ◽  
1996 ◽  
Vol 31 (7) ◽  
pp. 721-727 ◽  
Author(s):  
Nariman Ayyad ◽  
Bertram I. Cohen ◽  
Akira Ohshima ◽  
Erwin H. Mosbach

2001 ◽  
Vol 120 (6) ◽  
pp. 1459-1467 ◽  
Author(s):  
Olivier Rosmorduc ◽  
Raoul Poupon ◽  
Brigitte Hermelin

1983 ◽  
Vol 69 (3) ◽  
pp. 221-222 ◽  
Author(s):  
Maura Ludovici ◽  
Piero Dolara ◽  
Alfiero Costantini ◽  
Guido Barbagli ◽  
Anna Calzolai ◽  
...  

The metabolism of antipyrine was studied in 13 patients with cancer and bladder papillomas and in 11 control subjects, matched for interfering factors like smoking, diet, age and sex. The mean antipyrine half-life was significantly longer in patients with urinary tract cancer (14.7 ± 1.32 h SE) than in control subjects (11 ± 0.55 h SE) (P < 0.025); other clinical parameters did not vary.


Sign in / Sign up

Export Citation Format

Share Document